Xcout Intel
Vandria
Vandria is a biotechnology research company founded in September 2021 and based at the Biopôle campus in Epalinges, Switzerland. The company specializes in discovering first-in-class small molecules targeting mitochondrial function to treat age-related diseases. It operates with a small team focused on novel metabolic pathways.
Subscribe to see Vandria’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Vandria at a glance
Vandria is a biotechnology company headquartered in Switzerland. Its most recent funding round, Series A, raised $30.7M in August 2024.
Vandria funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $30.7M | 3 named | |
| Series A | $20.6M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Vandria competitors
A few of Vandria's closest competitors — see the full list of competitors and alternatives →
Cellvie AG is a biotechnology company based in Zurich, Switzerland, pioneering Therapeutic Mitochondria Transplantation to target cellular energy metabolism.
Rejuveron Life Sciences AG is a biotechnology company headquartered in Schlieren, Switzerland, focused on developing innovative therapeutics and therapies for aging-related diseases and longevity.
Endurance Biotech, Inc. is a biopharmaceutical company that develops first-in-class oral small molecules designed to restore mitochondrial and lysosomal function for the treatment of neurodegenerative, metabolic, and age-related diseases. Its lead clinical program, T-168, targets Parkinson's disease by addressing interconnected cellular systems, reducing neuroinflammation, and enhancing autophagy.
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
MitoRx Therapeutics is a platform biotechnology company headquartered in Oxford, England, developing novel mitochondrial-targeted therapeutics for life sciences.
Get Vandria's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Vandria in Xcout Intel
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access